NASDAQ:OMER Omeros (OMER) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free OMER Stock Alerts $3.52 -0.13 (-3.56%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$3.36▼$3.6750-Day Range$3.24▼$4.8952-Week Range$0.92▼$7.80Volume601,180 shsAverage Volume638,764 shsMarket Capitalization$221.30 millionP/E Ratio11.00Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Omeros alerts: Email Address Omeros MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish22.91% of Float Sold ShortDividend StrengthN/ASustainability-1.30Upright™ Environmental ScoreNews Sentiment0.89Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.30) to ($2.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.18 out of 5 starsMedical Sector613th out of 947 stocksPharmaceutical Preparations Industry281st out of 435 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Omeros. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.91% of the float of Omeros has been sold short.Short Interest Ratio / Days to CoverOmeros has a short interest ratio ("days to cover") of 20.2, which indicates bearish sentiment.Change versus previous monthShort interest in Omeros has recently decreased by 0.07%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOmeros does not currently pay a dividend.Dividend GrowthOmeros does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOmeros has received a 67.78% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Omeros is -1.30. Previous Next 3.8 News and Social Media Coverage News SentimentOmeros has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Omeros this week, compared to 2 articles on an average week.Search Interest6 people have searched for OMER on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows2 people have added Omeros to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omeros insiders have not sold or bought any company stock.Percentage Held by Insiders10.90% of the stock of Omeros is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.70% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Omeros are expected to grow in the coming year, from ($2.30) to ($2.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omeros is 11.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.01.Price to Earnings Ratio vs. SectorThe P/E ratio of Omeros is 11.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 188.85.Price to Book Value per Share RatioOmeros has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency About Omeros Stock (NASDAQ:OMER)Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Read More OMER Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMER Stock News HeadlinesMarch 12, 2024 | americanbankingnews.comOmeros (NASDAQ:OMER) Stock Price Crosses Above 200-Day Moving Average of $2.95March 3, 2024 | finance.yahoo.comOMER Aug 2024 5.000 putMarch 18, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 1, 2024 | gurufocus.comOmeros Corporation - Special Call TranscriptMarch 1, 2024 | gurufocus.comQ3 2020 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp at JPMorgan Healthcare Conference (Virtual) TranscriptMarch 1, 2024 | gurufocus.comQ4 2020 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ1 2021 Omeros Corp Earnings Call TranscriptMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 1, 2024 | gurufocus.comOmeros Corp at Bank of America NAPA Healthcare Conference (Virtual) TranscriptMarch 1, 2024 | gurufocus.comQ2 2021 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp Regulatory Update Call TranscriptMarch 1, 2024 | gurufocus.comQ3 2021 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp Omidria Call TranscriptMarch 1, 2024 | gurufocus.comQ4 2021 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ1 2022 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ2 2022 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ3 2022 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ4 2022 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ1 2023 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comQ2 2023 Omeros Corp Earnings Call TranscriptMarch 1, 2024 | gurufocus.comOmeros Corp To Provide Data Update Call TranscriptMarch 1, 2024 | gurufocus.comQ3 2023 Omeros Corp Earnings Call TranscriptFebruary 27, 2024 | wsj.comOmeros Corp.February 20, 2024 | finance.yahoo.comOmeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic MicroangiopathyFebruary 20, 2024 | businesswire.comOmeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic MicroangiopathyFebruary 17, 2024 | finance.yahoo.comOMER Mar 2024 4.000 putSee More Headlines Receive OMER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/18/2024Next Earnings (Estimated)3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:OMER CUSIP68214310 CIK1285819 Webwww.omeros.com Phone(206) 676-5000Fax206-676-5005Employees196Year Founded1994Profitability EPS (Most Recent Fiscal Year)$0.32 Trailing P/E Ratio11.00 Forward P/E RatioN/A P/E GrowthN/ANet Income$47.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-493.77% Return on Assets-33.47% Debt Debt-to-Equity Ratio10.80 Current Ratio2.39 Quick Ratio2.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book2.57Miscellaneous Outstanding Shares62,870,000Free Float56,013,000Market Cap$221.30 million OptionableOptionable Beta1.38 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Gregory A. Demopulos M.D. (Age 65)Co-Founder, Chairman, CEO & President Comp: $1.79MMr. Michael A. Jacobsen (Age 66)Chief Accounting Officer, VP of Finance & Treasurer Comp: $518.6kMr. Peter B. Cancelmo J.D. (Age 45)VP, General Counsel & Corporate Secretary Comp: $503.24kDr. Pamela Pierce Palmer M.D. (Age 61)Ph.D., Co-Founder Dr. George A. Gaitanaris M.D. (Age 67)Ph.D., Chief Scientific Officer & VP of Science Mr. Peter W. Williams (Age 56)Vice President of Human Resources Dr. Catherine A. Melfi Ph.D. (Age 65)Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems Ms. Nadia Dac (Age 54)VP & Chief Commercial Officer Dr. Andreas Grauer M.D. (Age 63)Chief Medical Officer More ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTREsperion TherapeuticsNASDAQ:ESPRAssembly BiosciencesNASDAQ:ASMBPyxis OncologyNASDAQ:PYXSConduit PharmaceuticalsNASDAQ:CDTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 26,085 shares on 3/11/2024Ownership: 5.040%Goldman Sachs Group Inc.Sold 64,645 shares on 3/1/2024Ownership: 0.067%Virtu Financial LLCBought 29,074 shares on 2/26/2024Ownership: 0.046%Citadel Advisors LLCSold 17,300 shares on 2/15/2024Ownership: 0.000%Wolverine Trading LLCSold 5,400 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions OMER Stock Analysis - Frequently Asked Questions Should I buy or sell Omeros stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OMER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMER, but not buy additional shares or sell existing shares. View OMER analyst ratings or view top-rated stocks. How have OMER shares performed in 2024? Omeros' stock was trading at $3.27 at the beginning of 2024. Since then, OMER shares have increased by 7.6% and is now trading at $3.52. View the best growth stocks for 2024 here. When is Omeros' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024. View our OMER earnings forecast. How were Omeros' earnings last quarter? Omeros Co. (NASDAQ:OMER) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.09. The biopharmaceutical company earned $30 million during the quarter, compared to analysts' expectations of $29.31 million. During the same quarter last year, the business earned ($0.39) earnings per share. What is Gregory A. Demopulos' approval rating as Omeros' CEO? 17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among the company's employees. What other stocks do shareholders of Omeros own? Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Array Technologies (ARRY), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Alibaba Group (BABA), Sangamo Therapeutics (SGMO), Verastem (VSTM), Bausch Health Companies (BHC) and Celldex Therapeutics (CLDX). Who are Omeros' major shareholders? Omeros' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.04%), Vanguard Group Inc. (5.04%), Stifel Financial Corp (3.01%), Corient Private Wealth LLC (1.06%), Northern Trust Corp (0.89%) and Royal Bank of Canada (0.81%). Insiders that own company stock include Arnold C Hanish, Gregory A Md Demopulos and Peter A Md Demopulos. View institutional ownership trends. How do I buy shares of Omeros? Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Omeros have any subsidiaries? The following companies are subsidiares of Omeros: Nura.Read More This page (NASDAQ:OMER) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.